Showing 1,121 - 1,140 results of 11,784 for search '(( 5 ((ng decrease) OR (nn decrease)) ) OR ( 50 ((ns decrease) OR (we decrease)) ))', query time: 0.60s Refine Results
  1. 1121

    IDD388 Polyhalogenated Derivatives as Probes for an Improved Structure-Based Selectivity of AKR1B10 Inhibitors by Alexandra Cousido-Siah (777034)

    Published 2016
    “…Next, by means of IC<sub>50</sub> measurements, X-ray crystallography, WaterMap analysis, and advanced binding free energy calculations with a quantum-mechanical (QM) approach, we have studied their structure–activity relationship (SAR) against both enzymes. …”
  2. 1122
  3. 1123

    MeHg Exposure Makes O-2A/OPCs More Oxidized, Suppresses BrdU Incorporation, and Decreases Cell Division in Clonal Assays by Zaibo Li (273729)

    Published 2013
    “…Cultures were then stained with A2B5 and anti-BrdU antibodies (to recognize all progenitors and those synthesizing DNA during the BrdU pulse, respectively). …”
  4. 1124
  5. 1125

    Discovery of Betulinic Acid Derivatives as Potent Intestinal Farnesoid X Receptor Antagonists to Ameliorate Nonalcoholic Steatohepatitis by Chenlu Zhang (508309)

    Published 2022
    “…Evidence showed that intestinal FXR antagonism exhibited remarkable metabolic improvements in mice. Herein, we developed a series of betulinic acid derivatives as potent intestinal FXR antagonists, and <b>F6</b> was identified as the most potent one with an IC<sub>50</sub> at 2.1 μM. …”
  6. 1126

    Discovery of Betulinic Acid Derivatives as Potent Intestinal Farnesoid X Receptor Antagonists to Ameliorate Nonalcoholic Steatohepatitis by Chenlu Zhang (508309)

    Published 2022
    “…Evidence showed that intestinal FXR antagonism exhibited remarkable metabolic improvements in mice. Herein, we developed a series of betulinic acid derivatives as potent intestinal FXR antagonists, and <b>F6</b> was identified as the most potent one with an IC<sub>50</sub> at 2.1 μM. …”
  7. 1127

    Combination of DNA Damage, Autophagy, and ERK Inhibition: Novel Evodiamine-Inspired Multi-Action Pt(IV) Prodrugs with High-Efficiency and Low-Toxicity Antitumor Activity by Xiao-Meng Liu (778197)

    Published 2023
    “…Among them, compound <b>10</b> exhibited a 118-fold enhancement in the IC<sub>50</sub> value compared to cisplatin and low toxicity to normal cells. …”
  8. 1128

    Combination of DNA Damage, Autophagy, and ERK Inhibition: Novel Evodiamine-Inspired Multi-Action Pt(IV) Prodrugs with High-Efficiency and Low-Toxicity Antitumor Activity by Xiao-Meng Liu (778197)

    Published 2023
    “…Among them, compound <b>10</b> exhibited a 118-fold enhancement in the IC<sub>50</sub> value compared to cisplatin and low toxicity to normal cells. …”
  9. 1129

    Combination of DNA Damage, Autophagy, and ERK Inhibition: Novel Evodiamine-Inspired Multi-Action Pt(IV) Prodrugs with High-Efficiency and Low-Toxicity Antitumor Activity by Xiao-Meng Liu (778197)

    Published 2023
    “…Among them, compound <b>10</b> exhibited a 118-fold enhancement in the IC<sub>50</sub> value compared to cisplatin and low toxicity to normal cells. …”
  10. 1130

    Combination of DNA Damage, Autophagy, and ERK Inhibition: Novel Evodiamine-Inspired Multi-Action Pt(IV) Prodrugs with High-Efficiency and Low-Toxicity Antitumor Activity by Xiao-Meng Liu (778197)

    Published 2023
    “…Among them, compound <b>10</b> exhibited a 118-fold enhancement in the IC<sub>50</sub> value compared to cisplatin and low toxicity to normal cells. …”
  11. 1131

    Combination of DNA Damage, Autophagy, and ERK Inhibition: Novel Evodiamine-Inspired Multi-Action Pt(IV) Prodrugs with High-Efficiency and Low-Toxicity Antitumor Activity by Xiao-Meng Liu (778197)

    Published 2023
    “…Among them, compound <b>10</b> exhibited a 118-fold enhancement in the IC<sub>50</sub> value compared to cisplatin and low toxicity to normal cells. …”
  12. 1132
  13. 1133
  14. 1134

    DataSheet_1_Host microRNAs are decreased in pediatric solid-organ transplant recipients during EBV+ Post-transplant Lymphoproliferative Disorder.docx by Ayantika Sen (13921581)

    Published 2022
    “…The objective of this study was to determine if changes in miR expression are associated with EBV+ PTLD. In this study, we have shown that miR-194 is significantly decreased in EBV+PTLD tumors and that additional miRs, including miRs-17, 19 and 106a are also reduced in EBV+PTLD as compared to EBV-PTLD. …”
  15. 1135

    DataSheet_1_Host microRNAs are decreased in pediatric solid-organ transplant recipients during EBV+ Post-transplant Lymphoproliferative Disorder.docx by Ayantika Sen (13921581)

    Published 2022
    “…The objective of this study was to determine if changes in miR expression are associated with EBV+ PTLD. In this study, we have shown that miR-194 is significantly decreased in EBV+PTLD tumors and that additional miRs, including miRs-17, 19 and 106a are also reduced in EBV+PTLD as compared to EBV-PTLD. …”
  16. 1136
  17. 1137
  18. 1138

    Variable included in analysis. by Molebatsi Moholola (20513371)

    Published 2025
    “…In the adjusted model we found that case management (Odds ratio [OR] 1.25; 95% Confidence Interval [CI] 1.08–1.44) versus no case management, 35–54 years old (1.43; 1.07–1.91) and 55+ year old (1.88; 1.35–2.61) versus 18–24-year-old increased odds of VL suppression whilst being male (0.72; 0.61–0.84) versus being female has decreased odd of VL suppression.…”
  19. 1139

    Full dataset of the study. by Molebatsi Moholola (20513371)

    Published 2025
    “…In the adjusted model we found that case management (Odds ratio [OR] 1.25; 95% Confidence Interval [CI] 1.08–1.44) versus no case management, 35–54 years old (1.43; 1.07–1.91) and 55+ year old (1.88; 1.35–2.61) versus 18–24-year-old increased odds of VL suppression whilst being male (0.72; 0.61–0.84) versus being female has decreased odd of VL suppression.…”
  20. 1140